BNTC
Benitec Biopharma Inc. (BNTC)
Healthcare • Biotechnology • $12.68 • MCap: 435,612,992
🌐
https://benitec.com • Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
Buy Decision Core
Total Score
32
Business Quality
1
Financial Strength
10
Growth Outlook
1
Momentum
4
Price Action
Current
12.68
52W High
16.52
52W Low
10.06
Above 50DMA
12.68 (0.00%)
Above 200DMA
12.10 (4.78%)
Relative Strength
Relative Strength
0.09
RS 3M
0.2
RS 6M
0.12
RS 9M
0.01
RS 12M
-0.09
Fundamentals
Revenue Growth
0%
Earnings Growth
0%
ROE
-0.30%
ROA
-0.20%
Valuation
PE (Fwd)
-1.35
PEG
0
P/B
2.38
Upside
90.59%
Risk
Beta
0.27
Short %
0.11
Risk Score
10.00
Analyst
Rating
strong_buy
Target
24.17
Beta
0.27
Analysts
0
Total Score
32
Upside
90.59%
Relative Strength
0.09
Beta
0.27
Why Buy?
- PEG Ratio below 1 (attractive valuation)
- Trading above 200 DMA
- Analyst upside exceeds 15%
Key Risks
- Negative ROE
- Weak long-term relative strength
Score Breakdown
Business
1
1
Financial
10
10
Growth
1
1
Valuation
12
12
Risk
2
2
Momentum
4
4
Technical
52W High: 16.52
52W Low: 10.06
Above 50DMA: 0.00%
Above 200DMA: 4.78%
Valuation
Forward PE: -1.35
PEG: 0
P/B: 2.38
Upside: 90.59%
Risk
Beta: 0.27
Short Float: 0.11%
ROE: -0.30%
ROA: -0.20%